A Study to Learn About the Study Medicine (Called Ritlecitinib) for the Potential Treatment of Severe Alopecia Areata in Children 6 to Less Than 12 Years of Age
An Interventional PK, PD, Phase 1, Open-Label Study to Investigate PK and PD of Multiple-Dose Ritlecitinib in Children 6 to Less
Than 12 Years of Age With Severe Alopecia Areata
Category & Conditions: Immune System Diseases and Conditions
Medicine: ritlecitinib (PF-06651600)
ClinicalTrials.gov Identifier (NCT): NCT05650333
Protocol ID: B7981031
Open Plain Language Summary Result:
Click here